Fracture risk in patients with monoclonal gammopathy of undetermined significance

British Journal of Haematology

Volumn 135, Issue 1, 2006, Pages 62-67

  Gregersen, Henrik ^a   Jensen, Paw ^a   Gislum, Mette ^b   Jørgensen, Birgit ^a   Sørensen, Henrik Toft ^b   Nørgaard, Mette ^b  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Benign monoclonal gammopathies; Fractures; Multiple myeloma; Population based study; Risk

Indexed keywords

IMMUNOGLOBULIN M;

ADOLESCENT; ADULT; ARTICLE; CHILD; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; FRACTURE; HUMAN; HUMAN CELL; INFANT; LIGHT CHAIN; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MONOCLONAL IMMUNOGLOBULINEMIA; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK FACTOR;

AGED; DENMARK; EPIDEMIOLOGIC METHODS; FEMALE; FRACTURES, BONE; HUMANS; MALE; MIDDLE AGED; PARAPROTEINEMIAS;

EID: 33748346437     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06269.x     Document Type: Article

References (26)

1. Abrahamsen, B., Andersen, I., Christensen, S.S., Skov Madsen, S. & Brixen, K. (2005) Utility of testing for monoclonal bands in serum of patients with suspected osteoporosis: retrospective, cross sectional study. BMJ, 330, 818-822.
2. Bataille, R., Chappard, D., Marcelli, C., Dessauw, P., Sany, J., Baldet, P. & Alexandre, C. (1989) Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone. Journal of Clinical Oncology, 7, 1909-1914.
3. Bataille, R., Chappard, D., Marcelli, C., Dessauw, P., Baldet, P., Sany, J. & Alexandre, C. (1991) Recruitment of new osteoblasts and osteoclast is the earliest critical event in the pathogenesis of human multiple myeloma. Journal of Clinical Investigation, 88, 62-66.
4. Bataille, R., Chappard, D. & Basle, M.F. (1996) Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies. Blood, 87, 4762-4769.
5. Charlson, M.E., Pompei, P., Ales, K.L. & MacKenzie, C.R. (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases, 40, 373-383.
6. Colls, B.M. & Lorier, M.A. (1975) Immunocytoma, cancer and other associations of monoclonal gammopathy: a review of 224 cases. New Zealand Medical Journal, 82, 221-226.
7. Diamond, T., Levy, S., Smith, A., Day, P. & Manoharan, A. (2001) Non-invasive markers of bone turnover and plasma cytokines differ in osteoporotic patients with multiple myeloma and monoclonal gammopathies of undetermined significance. Internal Medicine Journal, 31, 272-278.
8. Frank, L. (2000) Epidemiology. When an entire country is a cohort. Science, 287, 2398-2399.
9. Gregersen, H., Mellemkjaer, L., Ibsen, J.S., Sorensen, H.T., Olsen, J.H., Pedersen, J.O. & Dahlerup, J.F. (2000) Cancer risk in patients with monoclonal gammopathy of undetermined significance. American Journal of Hematology, 63, 1-6.
10. Gregersen, H., Ibsen, J.S., Mellemkjaer, L., Dahlerup, J.F., Olsen, J.H. & Sorensen, H.T. (2001) Mortality and causes of death in patients with monoclonal gammopathy of undetermined significance. British Journal of Haematology, 112, 353-357.
11. Hernandez, J.M., Suquia, B., Queizan, J.A., Fisac, R.M., Sanchez, J.J., Fernandez-Calvo, F.J., Garcia-Sanz, R., Olivier, C., Barez, A., Calmuntia, M.J., Garcia-Frade, J., Portero, J.A., Lopez, R., Aguilera, C., Navajo, J.A. & San-Miguel, J.F. (2004) Bone remodelation markers are useful in the management of monoclonal gammopathies. The Hematology Journal, 5, 480-488.
12. International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders; a report of the International Myeloma Working Group. British Journal of Haematology, 121, 749-757.
13. Kyle, R.A., Therneau, T.M., Rajkumar, S.V., Offord, J.R., Larson, D.R., Plevak, M.F. & Melton, L.J. (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. New England Journal of Medicine, 346, 564-569.
14. Kyle, R.A., Rajkumar, V. & Lust, J.A. (2004) Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma. In: Wintrobe's Clinical Hematology, 11th edn. (ed. by J.P. Greer, J. Foerster, J.N. Lukens, G.M. Rodgers, F. Paraskevas & B. Glader), pp. 2565. Lippincott Williams & Wilkins, Philadelphia.
15. Kyle, R.A., Therneau, T.M., Rajkumar, S.V., Larson, D.R., Plevak, M.F., Offord, J.R., Dispenzieri, A., Katzmann, J.A. & Melton 3rd, L.J. (2006) Prevalence of monoclonal gammopathy of undetermined significance. New England Journal of Medicine, 354, 1362-1369.
16. Laroche, M., Attal, M. & Dromer, C. (1996) Bone remodelling in monoclonal gammopathies of uncertain significance, symptomatic and nonsymptomatic myeloma. Clinical Rheumatology, 15, 347-352.
17. Laroche, M., Rolland, Y., Tackzuck, J., Constantin, A., Salles, J.P. & Masieres, B. (1998) Gammopathies of indeterminant significance and osteoporosis: association or coincidence?. The Medical Press, 27, 461-464.
18. Marx, R., Sawatari, Y., Fortin, M. & Broumand, V. (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. Journal of Oral and Maxillofacial Surgery, 63, 1567-1575.
19. Melton, L.J., Rajkumar, S.V., Khosla, S., Achenbach, S.J., Oberg, A.L. & Kyle, R.A. (2004) Fracture risk in monoclonal gammopathy of undetermined significance. Journal of Bone and Mineral Research, 19, 25-30.
20. Melton, L.J., Kyle, R.A., Achenbach, S., Oberg, A. & Rajkumar, S.V. (2005) Fracture risk with multiple myeloma: a population-based study. Journal of Bone and Mineral Research, 20, 487-493.
21. Musto, P., Falcone, A., Sanpaulo, G., Bodenissa, C., Cascavilla, N. & Melillo, L. (2003) Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial. Leukemia & Lymphoma, 44, 1545-1548.
22. Nickelsen, T. (2002) Data validity and coverage in the Danish National Health Registry. A literature review. Ugeskrift for Laeger, 164, 33-37.
23. Pecherstorfer, M., Seibel, M.J., Woitge, H.W., Horn, E., Schuster, J., Neuda, J., Sagaster, P., Kohn, H., Bayer, P., Thiebaud, D. & Ludwig, H. (1997) Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen. Blood, 90, 3743-3750.
24. Rosen, L.S., Gordon, D., Kaminski, M., Howell, A., Belch, A. & Mackey, J. (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer, 98, 1735-1744.
25. Storm, H.H., Michelsen, E.V., Clemmensen, I.H. & Pihl, J. (1997) The Danish Cancer Registry - history, content, quality and use. Danish Medical Bulletin, 44, 535-539.
26. Vejlgaard, T., Abildgaard, N., Jans, H., Nielsen, J.L. & Heickendorff, L. (1997) Abnormal bone turnover in monoclonal gammopathy of undetermined significance: analyses of type I collagen telopeptide, osteocalcin, bone-specific alkaline phosphatase and propeptides of type I and type III procollagens. European Journal of Haematology, 58, 104-108.